secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001625297-25-000059
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud

Indivior announces restructuring charges of $39-$50 million as part of Indivior Action Agenda
--------------------------------------------------------------------------------

- Headcount reductions expected to incur pre-tax severance charges of approximately $16 to $19 million in Q3 2025.
- Real estate consolidation and exit costs estimated at $15 to $22 million pre-tax, including leasehold improvements and asset write-downs.
- Consulting, legal, and tax planning expenses of about $8 to $9 million pre-tax, recognized in Q3 2025.
- Company is exploring strategic alternatives for OPVEE and its non-U.S. business, which could result in further one-time costs.
- Restructuring charges will be excluded from non-GAAP financial measures, consistent with reporting practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000059/0001625297-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000059/indv-20250826.htm
  HTML page:      https://secwatch.observer/filing/0001625297-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer